Programmed Death Ligand-1 Blocker [EPC]

21581 reported adverse events

Drugs of this class: AVELUMAB COSIBELIMAB DURVALUMAB

These side effects are most commonly reported by patients taking drugs of the Programmed Death Ligand-1 Blocker [EPC] class:

# Side effect Count
0 DEATH 4536
1 MALIGNANT NEOPLASM PROGRESSION 1762
2 PNEUMONITIS 947
3 DIARRHOEA 863
4 OFF LABEL USE 850
5 PYREXIA 814
6 RADIATION PNEUMONITIS 814
7 DISEASE PROGRESSION 761
8 FATIGUE 615
9 DYSPNOEA 604
See all common reactions for Programmed Death Ligand-1 Blocker [EPC]

Drugs of the Programmed Death Ligand-1 Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EPITHELITIS 16 0.7619
1 RADIATION PNEUMONITIS 814 0.3800
2 OESOPHAGOMEDIASTINAL FISTULA 7 0.3500
3 DIFFUSE UVEAL MELANOCYTIC PROLIFERATION 6 0.3158
4 BILE DUCT CANCER RECURRENT 7 0.2500
5 NON-SMALL CELL LUNG CANCER RECURRENT 64 0.2261
6 IMMUNOTOXICITY 22 0.1930
7 TUMOUR HYPERPROGRESSION 46 0.1855
8 PULMONARY RADIATION INJURY 11 0.1803
9 ARTERIAL INTRAMURAL HAEMATOMA 11 0.1375
See all enriched reactions for Programmed Death Ligand-1 Blocker [EPC]